[go: up one dir, main page]

BRPI9815772A - emprego de hidrogeno fumaratos de alquila para tratamento de psoríase, artrite psoriática, neurodermatites e enterite regional de crohn - Google Patents

emprego de hidrogeno fumaratos de alquila para tratamento de psoríase, artrite psoriática, neurodermatites e enterite regional de crohn

Info

Publication number
BRPI9815772A
BRPI9815772A BRPI9815772A BRPI9815772A BRPI9815772A BR PI9815772 A BRPI9815772 A BR PI9815772A BR PI9815772 A BRPI9815772 A BR PI9815772A BR PI9815772 A BRPI9815772 A BR PI9815772A BR PI9815772 A BRPI9815772 A BR PI9815772A
Authority
BR
Brazil
Prior art keywords
neurodermatitis
crohn
psoriasis
treatment
psoriatic arthritis
Prior art date
Application number
BRPI9815772A
Other languages
English (en)
Inventor
Rajendra K Joshi
Hans-Peter Strebel
Original Assignee
Fumapharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fumapharm Ag filed Critical Fumapharm Ag
Publication of BRPI9815772A publication Critical patent/BRPI9815772A/pt
Publication of BRPI9815772B1 publication Critical patent/BRPI9815772B1/pt
Publication of BRPI9815772B8 publication Critical patent/BRPI9815772B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

patente de invenção: <b>"emprego de hidrogeno fumaratos de alquila para tratamento de psoríase, artrite psoriática, neurodermatites e enterite regional de crohn"<d>. emprego de um ou vários hidrogeno fumaratos de alquila da fórmula geral: onde r é uma c~ 1-5~ alquila, opcionalmente em mistura com fumarato de dialquila da fórmula: e opcionalmente excipientes e veículos farmacêuticos costumeiros para preparação de uma composição farmacêutica na forma de microcomprimidos ou micropéletes para tratamento de psoríase, artrite psoriática, neurodermatite e enterite regional de crohn.
BRPI9815772 1998-03-31 1998-12-08 emprego de hidrogeno fumaratos de alquila para tratamento de psoríase, artrite psoriática, neurodermatites e enterite regional de crohn BRPI9815772B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19814358A DE19814358C2 (de) 1998-03-31 1998-03-31 Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
PCT/EP1998/007956 WO1999049858A1 (de) 1998-03-31 1998-12-08 Verwendung von alkylhydrogenfumaraten zur behandlung von psoriasis, psoriatischer arthritis, neurodermitis und enteritis regionalis crohn

Publications (3)

Publication Number Publication Date
BRPI9815772A true BRPI9815772A (pt) 2000-11-21
BRPI9815772B1 BRPI9815772B1 (pt) 2016-02-10
BRPI9815772B8 BRPI9815772B8 (pt) 2021-07-06

Family

ID=7863089

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9815772 BRPI9815772B8 (pt) 1998-03-31 1998-12-08 emprego de hidrogeno fumaratos de alquila para tratamento de psoríase, artrite psoriática, neurodermatites e enterite regional de crohn

Country Status (25)

Country Link
US (1) US6277882B1 (pt)
EP (1) EP1059920B1 (pt)
JP (1) JP3527890B2 (pt)
CN (1) CN1150898C (pt)
AT (1) ATE219936T1 (pt)
AU (1) AU745281B2 (pt)
BG (1) BG64744B1 (pt)
BR (1) BRPI9815772B8 (pt)
CA (1) CA2283915C (pt)
CZ (1) CZ291788B6 (pt)
DE (2) DE19814358C2 (pt)
DK (1) DK1059920T3 (pt)
EE (1) EE04702B1 (pt)
ES (1) ES2179551T3 (pt)
HU (1) HU228848B1 (pt)
IL (1) IL136835A (pt)
NO (1) NO327750B1 (pt)
NZ (1) NZ505341A (pt)
PL (1) PL191803B1 (pt)
PT (1) PT1059920E (pt)
RS (1) RS49658B (pt)
RU (1) RU2197233C2 (pt)
SK (1) SK285187B6 (pt)
TR (1) TR200001829T2 (pt)
WO (1) WO1999049858A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
HU230252B1 (hu) 2001-01-12 2015-11-30 Biogen Idec International Gmbh Fumársav-amid származékok
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
DE10217314A1 (de) * 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
ES2297461T3 (es) * 2003-09-09 2008-05-01 Fumapharm Ag Uso de derivados del acido fumarico para tratar la insuficiencia cardiaca y el asma.
DE10360869A1 (de) * 2003-09-09 2005-04-07 Fumapharm Ag Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
PL2801355T3 (pl) 2004-10-08 2015-10-30 Fwp Ip Aps Kompozycje farmaceutycznie o kontrolowanym uwalnianiu zawierające ester kwasu fumarowego
US20080004344A1 (en) * 2004-11-10 2008-01-03 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
EP1915334A2 (en) * 2005-07-07 2008-04-30 Aditech Pharma AB Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
DE602006011910D1 (de) 2005-07-07 2010-03-11 Aditech Pharma Ag Neue glucopyranoseester und glucofuranoseester von fumarsäurealkylestern und deren pharmazeutische verwendung
JP2009510137A (ja) * 2005-10-07 2009-03-12 アディテック・ファルマ・アクチボラゲット フマル酸エステルを含む制御放出医薬組成物
WO2007042035A2 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
EP2680010A1 (en) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Nrf2 screening assays and related methods and compositions
US20100130607A1 (en) * 2007-02-08 2010-05-27 Ralf Gold Neuroprotection in demyelinating diseases
WO2010022177A2 (en) 2008-08-19 2010-02-25 Xenoport, Inc. Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
EP2379063B2 (en) 2009-01-09 2021-02-24 Fwp Ip Aps Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
SI2718257T1 (en) 2011-06-08 2018-04-30 Biogen Ma Inc. PROCEDURE FOR PREPARATION OF HIGH QUALITY CRYSTALINIC DIMETHY OF FUMARAT
WO2013076216A1 (en) 2011-11-24 2013-05-30 Synthon Bv Controlled release particles comprising dimethyl fumarate
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
CN104169261A (zh) 2012-02-07 2014-11-26 什诺波特有限公司 富马酸吗啉代烃基酯化合物、药物组合物和使用方法
SG11201404705YA (en) 2012-02-07 2014-10-30 Biogen Idec Inc Pharmaceutical compositions containing dimethyl fumarate
KR101449114B1 (ko) * 2012-08-21 2014-10-13 바이오스펙트럼 주식회사 푸마르산을 유효성분으로 포함하는 항염 조성물
CA2882713A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140056973A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
US20140171504A1 (en) 2012-12-14 2014-06-19 Georgia Regents Research Institute, Inc. Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
ES2733961T3 (es) 2012-12-21 2019-12-03 Biogen Ma Inc Derivados de fumarato sustituidos con deuterio
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
NZ741985A (en) 2013-03-14 2019-12-20 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various diseases
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
CN105682648A (zh) 2013-08-26 2016-06-15 前进制药公司 用于以低的日剂量施用的含富马酸二甲酯的药物组合物
US9416096B2 (en) 2013-09-06 2016-08-16 Xenoport, Inc. Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
US20150079180A1 (en) 2013-09-18 2015-03-19 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
US9604922B2 (en) 2014-02-24 2017-03-28 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
RU2723559C2 (ru) * 2014-09-12 2020-06-16 Тобира Терапьютикс, Инк. Комбинированная терапия с применением препарата ценикривирок для лечения фиброза
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
PL3253377T3 (pl) 2015-02-08 2021-09-27 Alkermes Pharma Ireland Limited Kompozycje proleku fumaranu monometylu
EP3273951B1 (en) 2015-03-27 2020-07-29 Symbionyx Pharmaceuticals Inc. Compositions and methods for treating psoriasis
WO2017060400A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
CN105496804A (zh) * 2015-12-25 2016-04-20 知识产权全资有限公司 用于处理头发以及治疗头部牛皮藓的配方及其试剂盒和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) * 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) * 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
DE3127432A1 (de) * 1981-07-11 1983-02-03 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von fumarsaeuremonoester
US5214196A (en) * 1987-09-04 1993-05-25 Dexter Chemical Corporation Diethyl ester of di-glycyl fumaramide
US5242905A (en) * 1987-09-04 1993-09-07 Dexter Chemical Corporation Pharmaceutical compositions for the treatment of psoriasis
US5424332A (en) * 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE8714143U1 (de) * 1987-10-23 1988-03-24 Werler Kunststoffwerke GmbH & Co, 4760 Werl Sitz- und/oder Liegemöbel
DE3834794A1 (de) 1988-10-12 1990-04-19 F Schielein Oral zu verabreichendes mittel zur behandlung von psoriasis
WO1992012952A1 (en) * 1991-01-18 1992-08-06 Dexter Chemical Corporation Malic acid derivatives and compositions for the treatment of psoriasis
US5407772A (en) * 1993-11-30 1995-04-18 Xerox Corporation Unsaturated polyesters
US5972363A (en) * 1997-04-11 1999-10-26 Rohm And Haas Company Use of an encapsulated bioactive composition

Also Published As

Publication number Publication date
BRPI9815772B1 (pt) 2016-02-10
ATE219936T1 (de) 2002-07-15
BRPI9815772B8 (pt) 2021-07-06
SK7922000A3 (en) 2001-01-18
ES2179551T3 (es) 2003-01-16
IL136835A (en) 2005-05-17
JP2002509883A (ja) 2002-04-02
NZ505341A (en) 2002-04-26
NO327750B1 (no) 2009-09-14
IL136835A0 (en) 2001-06-14
DE59804704D1 (de) 2002-08-08
NO20002872L (no) 2000-06-06
HU228848B1 (en) 2013-06-28
CA2283915A1 (en) 1999-09-30
YU32000A (sh) 2002-03-18
PL341240A1 (en) 2001-03-26
CA2283915C (en) 2002-12-03
CZ291788B6 (cs) 2003-05-14
SK285187B6 (sk) 2006-08-03
HK1035134A1 (en) 2001-11-16
DE19814358A1 (de) 1999-10-07
AU2159399A (en) 1999-10-18
CN1150898C (zh) 2004-05-26
WO1999049858A1 (de) 1999-10-07
CZ20003086A3 (cs) 2000-11-15
CN1284870A (zh) 2001-02-21
TR200001829T2 (tr) 2000-11-21
HUP0103234A3 (en) 2003-11-28
EP1059920A1 (de) 2000-12-20
PL191803B1 (pl) 2006-07-31
NO20002872D0 (no) 2000-06-06
BG64744B1 (bg) 2006-02-28
JP3527890B2 (ja) 2004-05-17
HUP0103234A2 (hu) 2002-01-28
RS49658B (sr) 2007-09-21
EP1059920B1 (de) 2002-07-03
EE200000440A (et) 2001-12-17
BG104566A (en) 2001-01-31
DK1059920T3 (da) 2002-10-14
PT1059920E (pt) 2002-11-29
RU2197233C2 (ru) 2003-01-27
DE19814358C2 (de) 2002-01-17
EE04702B1 (et) 2006-10-16
US6277882B1 (en) 2001-08-21
AU745281B2 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
BRPI9815772A (pt) emprego de hidrogeno fumaratos de alquila para tratamento de psoríase, artrite psoriática, neurodermatites e enterite regional de crohn
US5091171B2 (en) Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
BR9910267A (pt) Microcomprimidos de ácido fumárico
BR9811923A (pt) Compostos possuindo atividade neuronal
MY103352A (en) Piperazinyl-heterocyclic compounds
WO2000047568A3 (en) 1,2-benzothiazepines for the treatment of hyperlipidemic diseases
NO20003546L (no) Anvendelse av progestin og en farmasøytisk sammensetning samt et kit inneholdende disse
MY115662A (en) Novel compounds with analgesic effect
TR200400228T4 (tr) Psöryazinin tedavisinde kullanılacak maddeler
DK0866791T3 (da) Diaminopyrimidiner, farmaceutiske præparater indeholdende disse og deres anvendelse som antibakterielle midler
ES2180729T3 (es) Tratamiento terapeutico combinado de las patologias hiperproliferantes.
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
MY103210A (en) Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds.
BR9810616A (pt) Inibidores de farnesil transferase em combinação com inibidores de hmg coa redutase para o tratamento do cancer
BR9810996A (pt) Composição farmacêutica
BR0009676A (pt) Método para o tratamento e/ou profilaxia de malária, usos de atovaquona e de uma combinação de atovaquona, proguanila e primaquina, combinação de atovaquona, proguanila e primaquina, kit, e, formulação farmacêutica
BR0113886A (pt) Composição, composição farmacêutica, tratamento de combinação para prevenir ou inibir a geração ou atividade de trombina num paciente, método para inibir ou prevenir a geração ou atividade de trombina num paciente, uso de uma composição ou tratamento de combinação, uso de uma composição, uso e kit
BR9813897A (pt) Derivados de bifenila como farmacêuticos
PT711163E (pt) Utilizacao de benzidamina no tratamento de estados patologicos provocados por tnf
HUP0000569A3 (en) Use of equilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states
BR9906350A (pt) Composição contendo cetanserina e l-carnitina ou uma alcanoil l-carnitina para o tratamento de crps
BR9910401A (pt) Nova formulação contendo paroxetina
PT795008E (pt) Linhas de celulas de condrocitos hipertroficos humanos